Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGPH20 with Gemcitabine and Nab-Paclitaxel in Borderline Resectable PDAC
NCT02487277Phase 2Terminated
- Start
- Jul 2015
- Primary completion
- May 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pegvorhyaluronidase alfa in pancreatic ductal adenocarcinoma (PDAC). Started Jul 2015; status: terminated.
02
Drugs
pegvorhyaluronidase alfa
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02487277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02487277.